RETREATMENT WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY BASED ON CHANGES IN VISUAL ACUITY AFTER INITIAL STABILIZATION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

• DOI: 10.1097/iae.0b013e318236e805
• Publication Date: 2012-03-13T12:10:17Z
• Authors: Roman Dunavoelgyi; Stefan Sacu; Katharina Eibenbe...; Stefan Palkovits; Christina Leydolt; Christian Pruente; Ursula Schmidt-Er...
• Keywords: Pro re nata; Regimen; Verteporfin

In Brief Purpose: To evaluate the 3-year therapeutic benefit of intravitreal bevacizumab in neovascular related macular degeneration (nAMD) a standard clinical setting involving 3 initial injections and pro re nata regimen as recommended PRONTO study. Methods: this interventional study, 181 eyes 160 consecutive patients with active meeting criteria for inclusion protocol anti–vascular endothelial growth factor therapy undergoing monotherapy were observed. Data treatment-naive (Group 1, n = 114) analyzed separately from that had undergone previous photodynamic plus triamcinolone 2, 67). Re-treatment based on outcome following official European label regimen. After 1 year continuous service at an academic referral center, follow-up was performed private practices collaboration center. Main parameters best-corrected visual acuity central retinal thickness. Results: years, decreased overall population (0.23 ± 0.16 to 0.21. P 0.002) both groups compared baseline (0.24 0.21 0.17 0.21, Group 0.03; 0.22 0.19 > 0.05), whereas thickness increased (291 92 319 110 μm, 0.01) 96 325 117 0.05; 290 83 308 0.05) because chronic cystic changes macula. Mean treatment rate 5.1 3.9 1) versus 3.7 2.7 0.01). Five cases severe intraocular inflammation after documented. Discussion: While functional morphological benefits persisted first treatment, time morphologic results disappointing during long-term loss main retreatment criterion. stabilization disease, monthly optical coherence tomography re-treatment morphologic, clinical, vision outcomes may increase efficacy under treatment. Patients age-related presenting indication treated followed-up re-treated according disease stabilization. maintenance poor changes.